Exp Mol Med.  2012 Jul;44(7):432-439.

Platinum nanoparticles reduce ovariectomy-induced bone loss by decreasing osteoclastogenesis

• Kim WK
• Kim JC
• Park HJ
• Sul OJ
• Lee MH
• Kim JS
• Choi HS

Abstract

Platinum nanoparticles (PtNP) exhibit remarkable antioxidant activity. There is growing evidence concerning a positive relationship between oxidative stress and bone loss, suggesting that PtNP could protect against bone loss by modulating oxidative stress. Intragastric administration of PtNP reduced ovariectomy (OVX)-induced bone loss with a decreased level of activity and number of osteoclast (OC) in vivo. PtNP inhibited OC formation by impairing the receptor activator of nuclear factor-kappaB ligand (RANKL) signaling. This impairment was due to a decreased activation of nuclear factor-kappaB and a reduced level of nuclear factor in activated T-cells, cytoplasmic 1 (NFAT2). PtNP lowered RANKL-induced long lasting reactive oxygen species as well as intracellular concentrations of Ca2+ oscillation. Our data clearly highlight the potential of PtNP for the amelioration of bone loss after estrogen deficiency by attenuated OC formation.

Keyword

NFAT2; osteoclasts; osteoporosis; ovariectomy; platinum nanoparticles; RANK ligand

MeSH Terms

Animals
Metal Nanoparticles/*administration & dosage
Mice
Mice, Inbred C57BL
NFATC Transcription Factors/metabolism
*Osteoclasts/drug effects/physiology
Osteoporosis/drug therapy
Ovariectomy/adverse effects
Oxidative Stress/drug effects
Platinum/*administration & dosage
*RANK Ligand/genetics/metabolism
Reactive Oxygen Species/metabolism
Signal Transduction